





## Relation of atrophic gastritis with *Helicobacter pylori*-CagA<sup>+</sup> and interleukin-1 gene polymorphisms

Rafaela Sierra, Clas Une, Vanessa Ramírez, Warner Alpízar-Alpízar, María I González, José A Ramírez, Antoine de Mascarel, Patricia Cuenca, Guillermo Pérez-Pérez, Francis Mégraud

Rafaela Sierra, Clas Une, Vanessa Ramírez, Warner Alpízar-Alpízar, Patricia Cuenca, Institute of Health Research, University of Costa Rica, San José 2060, Costa Rica  
María I González, Department of Statistics, University of Costa Rica, San José 2060, Costa Rica  
José A Ramírez, Department of Pathology, Calderón Guardia Hospital, Costa Rica, San José 2060, Costa Rica  
Antoine de Mascarel, Francis Mégraud, University Victor Segalen Bordeaux 2, 146, rue Leo-Saignat, Case 76, Bordeaux Cedex 33076, France  
Guillermo Pérez-Pérez, Departments of Medicine and Microbiology, New York University School of Medicine, NYU Langone Medical Center, 550 First Avenue, New York 10016, United States

Author contributions: Sierra R designed the research; Une C, Ramírez V, Alpízar-Alpízar W, Ramírez JA and De Mascarel A performed the research; Cuenca P contributed materials; Pérez-Pérez G and Mégraud F contributed analytic tools; Sierra R, Une C and González MI analyzed the data; Sierra R and Une C wrote the paper. Supported by The Centre Culturel et de Cooperation Scientifique de l'Ambassade de France au Costa Rica and the University of Costa Rica, No. 742-99-340

Correspondence to: Dr. Clas Une, Institute of Health Research, University of Costa Rica, San José 2060, Costa Rica. allan.une@ucr.ac.cr

Telephone: +506-2-2073290 Fax: +506-2-2075130

Received: May 14, 2008 Revised: September 16, 2008

Accepted: September 23, 2008

Published online: November 14, 2008

### Abstract

**AIM:** To determine the association of *Helicobacter pylori* (*H. pylori*) CagA<sup>+</sup> infection and pro-inflammatory polymorphisms of the genes interleukin (IL)-1RN and IL-1B with the risk of gastric atrophy and peptic ulcers in a dyspeptic population in Costa Rica, a country with high incidence and mortality of gastric cancer.

**METHODS:** Seven biopsy specimens, a fasting blood sample and a questionnaire concerning nutritional and sociodemographic factors were obtained from 501 consecutive patients who had undergone endoscopy for dyspeptic symptoms. A histopathological diagnosis was made. Pepsinogen concentrations were analyzed by enzyme linked immunosorbent assay (ELISA). Infection with *H. pylori* CagA<sup>+</sup> was determined by serology and polymerase chain reaction (PCR). IL-1B and IL-1RN polymorphisms genotyping was performed by PCR-restriction fragment length polymorphism (PCR-RFLP)

and PCR respectively.

**RESULTS:** In this dyspeptic population, 86% were *H. pylori* positive and of these, 67.8% were positive for CagA. Atrophic antral gastritis (AAG) was associated with CagA<sup>+</sup> status [odds ratio (OR) = 4.1; *P* < 0.000] and fruit consumption (OR = 0.3; *P* < 0.00). Atrophic body gastritis (ABG) was associated with pepsinogen PGI/PGII < 3.4 (OR = 4.9; *P* < 0.04) and alcohol consumption (OR = 7.3; *P* < 0.02). Duodenal ulcer was associated with CagA<sup>+</sup> (OR = 2.9; *P* < 0.04) and smoking (OR = 2.4; *P* < 0.04). PGI < 60 µg/L as well as PGI/PGII < 3.4 were associated with CagA<sup>+</sup>.

**CONCLUSION:** In a dyspeptic population in Costa Rica, *H. pylori* CagA<sup>+</sup> is not associated with ABG, but it is a risk factor for AAG. The pro-inflammatory cytokine polymorphisms IL-1B + 3945 and IL-1RN are not associated with the atrophic lesions of this dyspeptic population.

© 2008 The WJG Press. All rights reserved.

**Key words:** Atrophic gastritis; Pepsinogen; Peptic ulcers; *Helicobacter pylori*-CagA; Interleukins

**Peer reviewer:** Atsushi Nakajima, Professor, Yokohama City University Hospital, 3-9 Fukuura Kanazawaku, Yokohama 236, Japan

Sierra R, Une C, Ramírez V, Alpízar-Alpízar W, González MI, Ramírez JA, De Mascarel A, Cuenca P, Pérez-Pérez G, Mégraud F. Relation of atrophic gastritis with *Helicobacter pylori*-CagA<sup>+</sup> and interleukin-1 gene polymorphisms. *World J Gastroenterol* 2008; 14(42): 6481-6487 Available from: URL: <http://www.wjgnet.com/1007-9327/14/6481.asp> DOI: <http://dx.doi.org/10.3748/wjg.14.6481>

### INTRODUCTION

Colonization with *Helicobacter pylori* (*H. pylori*) is associated with atrophic gastritis, peptic ulcer and distal gastric cancer<sup>[1,2]</sup>. Nevertheless, many colonized individuals never develop these pathologies. Genetic characteristics of the host and the bacteria as well as environmental factors may be involved in the final clinical outcome<sup>[3]</sup>. The pathogenicity and virulence of *H. pylori* increases when the infecting strain expresses the *cagA* gene that codes for a highly immunogenic protein CagA, which is a marker

for the presence of the *cag* pathogenicity island (PAI)<sup>[4,5]</sup>. Moreover, the immune response of the host is considered a key event in the pathogenic process that leads to gastric cancer. A number of studies have reported that carriers of certain alleles in genes encoding proinflammatory and anti-inflammatory cytokines exhibit a stronger inflammatory response against *H pylori* and a marked inhibition of acid secretion resulting in an increased risk of gastric cancer and its precursors, atrophic gastritis and intestinal metaplasia<sup>[6,7]</sup>. However, this association has not been found in all studied populations<sup>[8]</sup>.

The development of atrophic gastritis is central in the multi-step process which leads to gastric cancer, and the risk increases with the severity and physical extension of the atrophic lesion<sup>[9,10]</sup>. Serum levels of pepsinogen I (PGI) and the ratio of PGI/PGII serum levels decrease significantly with increased extension and severity of atrophic gastritis and the presence of gastric cancer. Therefore, these parameters have been proposed as serological markers for those histopathological changes<sup>[11-13]</sup>. Costa Rica is one of the countries with the highest incidence and mortality rates of gastric cancer worldwide. The prevalence of *H pylori* associated gastritis is high from an early age<sup>[14]</sup>.

Recently, we found an association between the PGI/PGII ratio and atrophic body gastritis in dyspeptic patients<sup>[15]</sup>. In the present study, the same population was analyzed for associations of atrophic body and antral gastritis and presence of peptic ulcers with *H pylori* *CagA*<sup>+</sup> infection and pro-inflammatory interleukin-1 (*IL-1*) gene polymorphisms.

## MATERIALS AND METHODS

### Patients

As previously described<sup>[15]</sup>, between January and July, 2000, 800 consecutive patients referred to the endoscopy service at the Calderón Guardia Hospital in San José for dyspeptic symptoms were interviewed. This hospital is a tertiary hospital that, however, also provides gastroenterology service at primary and secondary levels. Patients were excluded if they were under 18 years of age, had not resided in Costa Rica for the previous two years, had received *H pylori* eradication therapy, had taken antibiotics during the 3 mo preceding endoscopy, had taken bismuth compounds at the time of endoscopy, had a history of gastric surgery, suffered from diseases associated with coagulation, or presented digestive bleeding. A total of 501 patients fulfilled the inclusion criteria and signed an informed consent form before 25 mL of fasting blood was obtained. The project had been previously approved by the ethic committees of the University of Costa Rica and the Hospital. A questionnaire with information concerning sociodemographic factors, family history, general health status, consumption of salt, coffee, alcohol, fruit, vegetables, and smoking habits was filled out<sup>[15]</sup>. Blood pressure and height and weight were recorded to calculate the body mass index.

### Endoscopy procedure

Seven biopsies were obtained: Two biopsies from the

middle part of the antrum were taken from the major and minor curvatures and two from the gastric body at the anterior and posterior walls of the central body for histopathological diagnosis. One biopsy from the antrum and one from the body were taken for culture and one from the antrum for rapid urease test<sup>[15]</sup>.

### Histological diagnosis

Sections of formaline-fixed and paraffin-embedded biopsies, stained with hematoxylin and eosin, were used for the histopathological diagnosis according to the Sydney Classification<sup>[16]</sup>. All slides were independently read by two specialists in gastric pathology (JA Ramírez in San José, Costa Rica, and A De Mascarel in Bordeaux, France). Cases with discrepant diagnoses were reviewed by both pathologists until a consensus was reached. A patient was considered to have: (1) atrophic body gastritis (ABG), if atrophy or metaplasia was present in any of the biopsies from the body; (2) atrophic antral gastritis (AAG), when atrophy was found in any of the biopsies from the antrum and not in the body; (3) non-atrophic gastritis (NAG), in the case of gastritis without atrophy, and (4) Normal mucosa, when no pathology was found in the antrum or the body and no granulocytic activity or lymphoid follicles were observed. In 22 of the patients, there was no histopathological diagnosis due to insufficient tissue in the biopsies<sup>[15]</sup>.

### *H pylori* status

Infection with *H pylori* was determined by histology, culture and serology. For histological detection, the slides were stained with toluidine blue. One biopsy from the antrum and one from the body were cultured for *H pylori*. Biopsies from the antrum and corpus were ground in brucella broth with an electric homogenizer. The suspensions were plated on two in-house media: A Wilkins Chalgren agar containing 10% human blood and antibiotics and a Columbia blood agar without antibiotics incubated for 10 d in a microaerobic atmosphere at 37°C. Standard identification was performed. Serum antibodies to *H pylori* were measured by an in-house enzyme linked immunosorbent assay (ELISA) developed in our laboratory and based on a modification of a previously described ELISA<sup>[17]</sup>. The antigen preparation and determination of cutoff points was previously reported<sup>[15]</sup>. A patient was considered positive for *H pylori* when positive by any of the three methods: culture or histology or serology and negative when none of the methods were positive.

### *CagA* status

The *cagA* status was determined by polymerase chain reaction (PCR) on isolated strains using primers *cagA*<sub>1</sub>-*A*<sub>2</sub> and, if negative, a second set of primers, *cagA*<sub>3</sub>-*A*<sub>4</sub>, were used<sup>[18]</sup>. Serum antibodies to *CagA* were measured by ELISA as described by Blaser *et al*, 1995<sup>[19]</sup>. A patient was considered positive for *H pylori* *CagA*<sup>+</sup> infection when positive by PCR and/or serology.

### Serum pepsinogen concentrations

The concentrations of PGI and PGII in sera were

measured by an enzyme immunosorbent assay (EIA) (Eiken Chemical Company, Tokyo, Japan) according to the manufacturers' recommendations. The validation of pepsinogen levels for this population was described previously<sup>[15]</sup>. In order to detect as many patients as possible with ABG, a cut-off point that favored sensitivity was selected. The optimal cut-off point for this population had been set at a PGI/PGII ratio of 3.4, which gave a sensitivity of 91.2% and a specificity of 38.5%<sup>[15]</sup>. The predictive value for a positive sample was 11.2% and for a negative 98.1%. Pepsinogen levels could not be measured in 51 patients, because insufficient amounts of blood were obtained or because the patients did not accept being bled.

### IL-1B and IL-1RN genotyping

IL-1B polymorphism analysis was performed by PCR-restriction fragment length polymorphism (PCR-RFLP). 100 ng of genomic DNA were amplified with the primers and PCR conditions previously reported<sup>[20]</sup>. The PCR products for IL-1B + 3954 were digested with the restriction enzyme *TaqI* and the allele designation for this polymorphism was the same as previously reported<sup>[21]</sup>.

Genomic DNA (100 ng) was amplified using the same primers and PCR conditions as previously reported for *IL-1RN*<sup>[20]</sup>. For statistical analysis purposes and because of the low frequency of alleles 3, 4 and 5, this polymorphism was treated as biallelic by dividing alleles into short and long categories, in which the short allele has two repeats (allele 2) and long allele has more than two repeats (allele L). For 110 (22%) patients genotyping was not done because of insufficient leukocyte samples or problems in the isolation or analysis of the DNA.

### Statistical analysis

$\chi^2$  statistics were used for comparing genotype frequencies among the groups studied and to assess Hardy-Weinberg equilibrium for each of the loci studied. Allelic frequencies were assessed using Estimating Haplotype Frequencies (EH) (available at [ftp://linkage.rockefeller.edu/software/eh/](http://linkage.rockefeller.edu/software/eh/)). Polytomic logistic regression was used to compare genotypic frequencies among the groups studied here using STATA/SE 8.0 (STATA Corporation, College Station, TX).

A logistic regression model was used to calculate the odd ratios (ORs) for (dependent variable): (1) ABG compared to dyspepsia without atrophic gastritis; (2) AAG compared to dyspepsia without atrophic gastritis; (3) Gastric ulcer compared to all of the others; (4) Duodenal ulcer compared to the rest; (5) Levels of PGI < 60  $\mu$ g/L compared to levels of PGI > 60  $\mu$ g/L; and (6) Values of PGI/PGII < 3.4 compared to values of PGI/PGII > 3.4. The systematic independent variables were *H pylori* CagA infection, IL-1B + 3954 allele T carriers, IL-1RN allele 2 carriers, and those that had been associated with the dependent variables in a previous study of the same population: Age, sex, overweight, frequency of alcohol and fruit consumption and the PGI/PGII ratio for atrophic gastritis and age; gender and cigarette smoking for peptic ulcers<sup>[15]</sup>. The logistic regression analyses

**Table 1** Sex, age and pepsinogen levels according to histopathological diagnosis

	Sex (M/F) (n = 155/324)	Age (yr), mean (95% CI)	PGI (mg/L), mean (95% CI)	PGI/PGII, mean (95% CI)
Normal	9/12	38 (30.7-45.7)	39.7 (27.9-51.5)	4.3 (3.3-5.4)
NAG	104/225	45 (43.2-46.6)	53.1 (49.4-56.9)	3.3 (3.1-3.6)
AAG	26/67	50 (47.0-52.8)	60.2 (52.9-67.5)	3.3 (2.9-3.7)
ABG	16/20	53 (48.2-57.6)	36.1 (26.6-45.5) <sup>1</sup>	1.9 (1.5-2.4) <sup>1</sup>

<sup>1</sup>P ≤ 0.001, ABG vs the rest.

were performed including either, only *H pylori* infected individuals or, all of the participants. The association was determined as an OR at a confidence interval of 95%. Statistical significance was set at P < 0.05. The software STATA/SE 8.0 (STATA Corporation, College Station, TX) was used for the statistical analysis.

## RESULTS

In this study, 501 patients were included, 338 women with an average age of 46.3 years, and 163 men with an average age of 46 years. The mean age was higher in groups with the most severe pathologies (Table 1).

### Pepsinogen

PGI y PGII concentrations could be measured in 450 patients. Serum concentrations of PGI as well as the PGI/PGII ratio were lower in patients with ABG as compared to other dyspeptic patients (Table 1). Dyspeptic patients with a ratio below 3.4 were at increased risk of having ABG compared to those with a ratio higher than 3.4 (Table 2).

### *H pylori* CagA<sup>+</sup>

The frequency of *H pylori* infection was 86%, out of which 67.8% were CagA<sup>+</sup>, however, the prevalence varied according to the pathology. Patients with a normal histopathological diagnosis, although few, showed a lower incidence of infection with *H pylori* and *H pylori* CagA<sup>+</sup> (15.0% and 5.3%, respectively) as compared to the rest, NAG (88.9% and 55.5%), AAG (93.3% and 81.6%) or ABG (82.9% and 58.8%). The prevalence of infection with *H pylori* and *H pylori* CagA<sup>+</sup> for gastric ulcer was 100% and 52.2%, respectively, and for duodenal ulcer 98% and 85%, respectively. Among patients with PGI/PGII < 3.4, the prevalence of infection with *H pylori* was 87.7% and with *H pylori* CagA<sup>+</sup> 61.3% while that of patients with ratios > 3.4 were at 82.1% and 50.0%. *H pylori* CagA<sup>+</sup> was associated with a PGI/PGII ratio < 3.4 and PGI < 60  $\mu$ g/L (Table 3).

### Polymorphisms: IL-1RN and IL-1B + 3954

Genotyping of the cytokine polymorphisms was successfully performed in 371 patients (74%). Genotypic distributions of IL-1RN and IL-1B + 3954 polymorphisms were not significantly different among the studied groups (Table 4). There was Hardy-Weinberg

**Table 2 OR with 95% CI for the association between atrophic gastritis and risk factors in dyspeptic *H pylori*-status<sup>+</sup> patients<sup>1</sup>**

	Atrophic gastritis in antrum (AAG)			Atrophic gastritis in body (ABG)		
	OR	95% CI	P	OR	95% CI	P
Age > 50 yr	1.6	0.8-3.0	0.2	2.8	1.0-7.7	0.04
Men	0.6	0.3-1.2	0.2	1.2	0.4-3.5	0.7
Overweight (BMI > 25.9)	0.7	0.3-1.2	0.2	0.8	0.3-2.0	0.6
Fruit consumption						
0-1 times/wk	1.0			1.0		
2-6 times/wk	0.4	0.2-0.8	0.01	1.4	0.4-4.6	0.6
More than 6 times/wk	0.3	0.2-0.7	0.00	0.7	0.2-2.6	0.6
Alcohol consumption						
No consumption	1.0			1.0		
Weekends or more	3.0	0.8-12	0.1	7.3	1.5-35.8	0.02
<i>H pylori</i>						
CagA status <sup>+</sup>	4.1	1.9-9.0	0.000	1.2	0.4-3.5	0.7
IL-1B + 3954						
T carriers vs CC	0.6	0.3-1.2	0.16	0.9	0.3-2.4	0.8
IL-1RN						
2 carriers vs LL	1.4	0.8-2.6	0.3	1.3	0.5-3.5	0.6
PGI/PGII ≤ 3.4	1.4	0.7-2.8	0.3	4.9	1.1-22.5	0.04

<sup>1</sup>Logistic regression, AAG and ABG vs non-atrophic gastritis.

**Table 3 OR with 95% CI for the association between PGI and PGI/PGII and risk factors in dyspeptic *H pylori*-status<sup>+</sup> patients<sup>1</sup>**

	PGI < 60 µg/L			PGI/PGII < 3.4		
	OR	95% CI	P	OR	95% CI	P
Age > 50 yr	1.1	0.6-1.8	0.8	1.6	1.0-2.7	0.07
Men	1.6	0.9-2.7	0.09	0.7	0.4-1.2	0.2
Overweight (BMI > 25.9)	1.0	0.6-1.7	0.9	0.6	0.4-1.0	0.04
Fruit consumption						
0-1 times/wk	1.0			1.0		
2-6 times/wk	0.6	0.3-1.2	0.1	1.6	0.9-2.8	0.1
More than 6 times/wk	1.3	0.7-2.4	0.4	1.3	0.7-2.4	0.4
Alcohol consumption						
No consumption	1.0			1.0		
Weekends or more	0.2	0.05-1.1	0.07	1.8	0.5-6.3	0.3
<i>H pylori</i>						
CagA status <sup>+</sup>	2.5	1.4-4.3	0.002	1.8	1.1-3.0	0.03
IL-1B + 3954						
T carriers vs CC	1.2	0.7-1.9	0.5	0.8	0.5-1.3	0.3
IL-1RN						
2 carriers vs LL	1.6	1.0-2.7	0.06	0.9	0.6-1.4	0.3

<sup>1</sup>Logistic regression, PGI < 60 µg/L vs PGI > 60 µg/L and PGI/PGII < 3.4 vs PGI/PGII > 3.4.

equilibrium for the IL-1RN locus in the groups used here as controls (dyspepsia without atrophic gastritis and all of the groups together excluding ABG). However, in the case of the IL-1B + 3954 polymorphism, there was no equilibrium for any of the control groups (data not shown). The frequency of the allele 2 for IL-1RN polymorphism was not significantly different in normal patients, compared to those with some type of gastritis (Table 4).

**Logistic regression atrophic gastritis**

An increased risk of ABG was observed among patients

**Table 4 Genotypic and allelic frequencies for the studied groups n (%)**

	Normal	NAG	AAG	ABG
IL-1RN				
L*L	11/17 (65)	124/253 (49)	33/76 (43)	13/25 (52)
L*2	6/17 (35)	107/253 (42)	31/76 (41)	8/25 (32)
2*2	0/17 (0)	22/253 (9)	12/76 (16)	4/25 (16)
Allelic freq. 2	0.16	0.27	0.29	0.28
IL-1B + 3954				
CC	12/18 (66)	123/250 (49)	46/77 (60)	13/26 (50)
CT	5/18 (28)	121/250 (48)	30/77 (39)	13/26 (50)
TT	1/18 (6)	6/250 (3)	1/77 (1)	0/26 (0)
Allelic freq. T	0.22	0.26	0.20	0.24

**Table 5 OR with 95% CI for the association between peptic ulcers and risk factors in dyspeptic *H pylori*-status<sup>+</sup> patients<sup>1</sup>**

	Gastric ulcer			Duodenal ulcer		
	OR	95% CI	P	OR	95% CI	P
Age > 50 yr	3.3	1.2-9.1	0.02	0.8	0.4-1.8	0.6
Men	0.3	0.9-1.3	0.1	3.2	1.5-7.2	0.004
Present smoker	1.2	0.3-4.7	0.8	2.4	1.0-5.6	0.04
<i>H pylori</i>						
CagA status <sup>+</sup>	0.7	0.3-1.8	0.4	2.9	1.0-7.9	0.04
IL-1B + 3954						
T carriers vs CC	1.2	0.5-3.2	0.7	0.9	0.4-1.9	0.8
IL-1RN						
2 carriers vs LL	1.4	0.5-3.6	0.5	0.7	0.3-1.4	0.3

<sup>1</sup>Logistic regression, Peptic ulcer vs no peptic ulcer.

older than 50 years, those consuming alcohol and those with a PGI/PGII ratio < 3.4. Patients infected with CagA<sup>+</sup> strains of *H pylori* and those with lower consumption of fruit were at higher risk of developing AAG, (Table 2). The presence of pro-inflammatory alleles, IL-1B + 3954T and IL-1RN\*2, did not confer an enhanced risk of any type of atrophy (Table 2).

**Peptic ulcers**

Duodenal ulcer was more frequent than gastric ulcer (52/24) in both genders. However, it was twice as common in males and the average age of patients with duodenal ulcer (average 46; 95% IC, 42.5-50.2) was lower than that of those with gastric ulcer (average 58; 95% CI, 52.2-63.6). Males, smokers and patients infected with *H pylori* CagA<sup>+</sup> were at increased risk of duodenal ulcer (Table 5).

**DISCUSSION**

While NAG associated with *H pylori* is more prevalent in industrialized countries, atrophic gastritis is more common in the developing world. The reason for this is probably a combination of effects caused by *H pylori* and other infections in early childhood, as well as other environmental factors and genetic composition<sup>[4,22]</sup>. Atrophic gastritis initiates in the antrum and may extend upwards towards the gastric body, often resulting in more severe atrophic gastritis with increased age<sup>[9]</sup>. It has been reported in sev-

eral studies that infection with *H pylori* CagA<sup>+</sup> increases the risk of atrophic gastritis and gastric cancer<sup>[4,23]</sup>. In the present study, infection with *H pylori* CagA<sup>+</sup> is associated with atrophic gastritis of the antrum, but not of the body, results which are in accordance with those reported by Oksanen *et al.*, 2000<sup>[24]</sup>. Indeed, in a stomach affected by ABG, the microenvironment is more hostile for the survival and growth of *H pylori* promoting spontaneous eradication of the bacteria and a progressive decline in concentrations of serum antibodies to *H pylori*<sup>[25-27]</sup>. Atrophic gastritis has been considered as a consequence of prolonged gastritis caused by *H pylori* and the association between *H pylori* infection and gastric cancer appears stronger when the infection is recorded several years before the onset of cancer<sup>[28]</sup>. Therefore, in our study, the association of *H pylori* CagA<sup>+</sup> with ABG may be underestimated, taking into account that patients belong to a population in which *H pylori*-associated gastritis is prevalent from childhood<sup>[14]</sup>. *H pylori* and its virulence factor CagA may be involved in processes during the early stages of inflammation of the antrum that lead to extension of atrophic gastritis towards the gastric body<sup>[29]</sup>.

In concordance with other studies, infection with *H pylori*-CagA<sup>+</sup> is associated with low PGI/PGII ratios<sup>[24]</sup>. Several studies have reported an association of low PGI concentrations and low PGI/PGII ratios with precancerous lesions as well as with gastric cancer<sup>[30-32]</sup>. In the study population, PGI/PGII values below 3.4 were previously shown to be associated with ABG but not with AAG<sup>[13]</sup>. The studies performed in Costa Rica to date indicate low specificities of the pepsinogen test for the detection of gastric cancer and ABG (64% and 38.5%, respectively). Nevertheless, its high negative predictive values (99.5% and 98%) could make the PG test useful to eliminate, from subsequent steps of screening programs, persons that are unlikely to develop gastric cancer<sup>[15,33]</sup>.

Our results fail to demonstrate an association between AAG, ABG and pro-inflammatory polymorphisms IL-1B + 3945 or IL-1RN. The control group consisted of dyspeptic patients of which a large majority suffered from some inflammatory condition (NAG). In a previous study, performed by our group, among participants in a program at the Center for Early Detection of Gastric Cancer in Costa Rica, it was found that IL-1B + 3945T and IL-1RN\*2 were associated with an increased risk of gastric cancer: OR = 3.7 *P* = 0.007 and OR = 2.9; *P* = 0.03 respectively<sup>[34]</sup>. In this study, the control groups were normal individuals as judged by X-ray (double contrast, gastric study).

The combination of IL-1B + 3954 and IL-1RN pro-inflammatory genotypes, or that of proinflammatory alleles and CagA, did not reveal any association with any particular pathology when included in the logistic regression analysis (data not shown).

Recent reports concerning the association of polymorphisms enhancing the expression of the gene IL-1B with atrophic gastritis, gastric cancer and peptic ulcer, diverge in their results<sup>[35]</sup>. Several studies link these polymorphisms to a reduction in acid secretion, gastric in-

flammation, atrophy, and gastric cancer<sup>[16,20,36-38]</sup>, whereas others do not<sup>[39-42]</sup>. These contradictory results may be related to the characteristics of the studied population, the methodology used, regional differences with regard to the frequencies of pro- or anti-inflammatory polymorphisms, the prevalence and time of infection with *H pylori* and the characteristics of the infecting strain, as well as diet and other environmental factors that interact with and influence the final result of the pathological process initiated by the infection<sup>[43-45]</sup>.

The results of the present study show that consumption of fruit, even in modest quantities, diminishes the risk of AAG, but has no effect on more advanced atrophy, ABG. It has been suggested that the protective properties of fruit are due to its content of antioxidants that would counteract the oxidative stress induced by *H pylori*<sup>[46]</sup>.

The data presented here are in accordance with reports from other laboratories stating that CagA<sup>+</sup> individuals are at higher risk of developing duodenal ulcers<sup>[47,48]</sup>. Although patients with duodenal ulcer have reduced risk of gastric cancer, *H pylori* predisposes to both conditions<sup>[49]</sup>. These different consequences may be a result of the host response to the infection. It has been reported that an increase in acidity predisposes for duodenal ulceration whereas hypochlorhydria is associated with a higher risk of developing gastric cancer<sup>[50]</sup>.

In summary, this study does not permit the conclusion that there exists no association between infection with CagA<sup>+</sup> *H pylori* and ABG, because *H pylori* is spontaneously eradicated with the severity and extension of atrophic lesions. Future epidemiologic investigations should eliminate the inherent biases of sub-detection of *H pylori* and specially *H pylori* CagA<sup>+</sup>. The true relationships between *H pylori* and diseases of the upper gastrointestinal tract are highly complex. It is of crucial importance to identify the factors that direct the initial inflammatory reactions to different gastric pathologies and decipher the mechanisms involved those processes, not only for the understanding of carcinogenesis, but also for the prevention and detection of diseases related to *H pylori*.

## ACKNOWLEDGMENTS

The authors gratefully acknowledge Drs. Ricardo Barahona, Rigoberto Salas-Aguilar, Alessia Ávalos, Gerardo Avendaño and Rolando Páez, at the Calderón Guardia Hospital for performing the gastroscopic examinations and providing the biopsies used in the study. We also thank Victor Castillo for excellent technical assistance and Anne Chinnock for revising the manuscript.

## COMMENTS

### Background

Costa Rica has a high incidence of and mortality from gastric cancer. Infection with *H pylori* and proinflammatory interleukin (IL) gene polymorphisms have been associated with precancerous gastric lesions and gastric adenocarcinoma. Atrophic gastritis may lead to the development of cancer. This study addresses the association of atrophic antral and body gastritis with infection with

*H pylori*-CagA+ strains and IL-1 gene polymorphisms in a dyspeptic population in an area at high risk of gastric cancer in Costa Rica.

### Research frontiers

In a dyspeptic population in Costa Rica, *H pylori* CagA<sup>+</sup> is not associated with atrophic body gastritis, but it is a risk factor for atrophic antral gastritis (AAG). The pro-inflammatory cytokine polymorphisms IL-1B + 3945 and IL-1RN are not associated with the atrophic lesions.

### Innovations and breakthroughs

Studies of various populations have indicated an association between gastric cancer and *H pylori*-CagA as well as proinflammatory gene variants. The etiology of gastric cancer varies among populations. The present study shows that *H pylori*-CagA is related to active AAG, but not to more advanced atrophy of the gastric body in a high-risk population. It is speculated that the bacteria may have disappeared at this stage. Furthermore, the study demonstrates no relation between two proinflammatory IL-1 gene polymorphisms and atrophy of the stomach in dyspeptic patients.

### Applications

In developing countries with high incidence of *H pylori* infection and dyspepsia it is not feasible to screen large populations with endoscopy. The information generated here may be used to create a battery of markers to detect risk factors for gastric cancer from a blood sample. Screening and intervention may then be concentrated on people with a high-risk profile.

### Peer review

The report is interesting. It could be useful in clinical settings. It indicated that in a dyspeptic population in Costa Rica, *H pylori* CagA<sup>+</sup> is a risk factor for AAG.

## REFERENCES

- Graham DY. Helicobacter pylori infection in the pathogenesis of duodenal ulcer and gastric cancer: a model. *Gastroenterology* 1997; **113**: 1983-1991
- Stemmermann GN, Fenoglio-Preiser C. Gastric carcinoma distal to the cardia: a review of the epidemiological pathology of the precursors to a preventable cancer. *Pathology* 2002; **34**: 494-503
- Matysiak-Budnik T, Megraud F. Helicobacter pylori infection and gastric cancer. *Eur J Cancer* 2006; **42**: 708-716
- Huang JQ, Zheng GF, Sumanac K, Irvine EJ, Hunt RH. Meta-analysis of the relationship between cagA seropositivity and gastric cancer. *Gastroenterology* 2003; **125**: 1636-1644
- Wu AH, Crabtree JE, Bernstein L, Hawtin P, Cockburn M, Tseng CC, Forman D. Role of Helicobacter pylori CagA+ strains and risk of adenocarcinoma of the stomach and esophagus. *Int J Cancer* 2003; **103**: 815-821
- Machado JC, Figueiredo C, Canedo P, Pharoah P, Carvalho R, Nabais S, Castro Alves C, Campos ML, Van Doorn LJ, Caldas C, Seruca R, Carneiro F, Sobrinho-Simoes M. A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma. *Gastroenterology* 2003; **125**: 364-371
- Zabaleta J, Camargo MC, Puzuelo MB, Fonham E, Schneider BG, Scinschi LA, Ferrante W, Balart L, Correa P, Ochoa AC. Association of interleukin-1beta gene polymorphisms with precancerous gastric lesions in African Americans and Caucasians. *Am J Gastroenterol* 2006; **101**: 163-171
- Furuta T, Shirai N, Sugimoto M. Controversy in polymorphisms of interleukin-1beta in gastric cancer risks. *J Gastroenterol* 2004; **39**: 501-503
- Correa P. Human gastric carcinogenesis: a multistep and multifactorial process--First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. *Cancer Res* 1992; **52**: 6735-6740
- Sipponen P, Kekki M, Haapakoski J, Ihmaki T, Siurala M. Gastric cancer risk in chronic atrophic gastritis: statistical calculations of cross-sectional data. *Int J Cancer* 1985; **35**: 173-177
- Sasazuki S, Inoue M, Iwasaki M, Otani T, Yamamoto S, Ikeda S, Hanaoka T, Tsugane S. Effect of Helicobacter pylori infection combined with CagA and pepsinogen status on gastric cancer development among Japanese men and women: a nested case-control study. *Cancer Epidemiol Biomarkers Prev* 2006; **15**: 1341-1347
- Dinis-Ribeiro M, Yamaki G, Miki K, Costa-Pereira A, Matsukawa M, Kurihara M. Meta-analysis on the validity of pepsinogen test for gastric carcinoma, dysplasia or chronic atrophic gastritis screening. *J Med Screen* 2004; **11**: 141-147
- Oishi Y, Kiyohara Y, Kubo M, Tanaka K, Tanizaki Y, Ninomiya T, Doi Y, Shikata K, Yonemoto K, Shiota T, Matsumoto T, Iida M. The serum pepsinogen test as a predictor of gastric cancer: the Hisayama study. *Am J Epidemiol* 2006; **163**: 629-637
- Sierra R, Munoz N, Pena AS, Biemond I, van Duijn W, Lamers CB, Teuchmann S, Hernandez S, Correa P. Antibodies to Helicobacter pylori and pepsinogen levels in children from Costa Rica: comparison of two areas with different risks for stomach cancer. *Cancer Epidemiol Biomarkers Prev* 1992; **1**: 449-454
- Sierra R, Une C, Ramirez V, Gonzalez MJ, Ramirez JA, de Mascarel A, Barahona R, Salas-Aguilar R, Paez R, Avendano G, Avalos A, Broutet N, Megraud F. Association of serum pepsinogen with atrophic body gastritis in Costa Rica. *Clin Exp Med* 2006; **6**: 72-78
- Price AB. The Sydney System: histological division. *J Gastroenterol Hepatol* 1991; **6**: 209-222
- Perez-Perez GI, Dworkin BM, Chodos JE, Blaser MJ. Campylobacter pylori antibodies in humans. *Ann Intern Med* 1988; **109**: 11-17
- Labigne A, Lamouliatte H, Birac C, Sedallian A, Megraud F. Distribution of the cagA gene among Helicobacter pylori strains associated with peptic ulcer. *Am J Gastroenterol* 1994; **89**: 1326
- Blaser MJ, Perez-Perez GI, Kleanthous H, Cover TL, Peek RM, Chyou PH, Stemmermann GN, Nomura A. Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach. *Cancer Res* 1995; **55**: 2111-2115
- El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young HA, Herrera J, Lissowska J, Yuan CC, Rothman N, Lanyon G, Martin M, Fraumeni JF Jr, Rabkin CS. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. *Nature* 2000; **404**: 398-402
- Zeng ZR, Hu PJ, Hu S, Pang RP, Chen MH, Ng M, Sung JJ. Association of interleukin 1B gene polymorphism and gastric cancers in high and low prevalence regions in China. *Gut* 2003; **52**: 1684-1689
- Smith VC, Genta RM. Role of Helicobacter pylori gastritis in gastric atrophy, intestinal metaplasia, and gastric neoplasia. *Microsc Res Tech* 2000; **48**: 313-320
- Kuipers EJ, Perez-Perez GI, Meuwissen SG, Blaser MJ. Helicobacter pylori and atrophic gastritis: importance of the cagA status. *J Natl Cancer Inst* 1995; **87**: 1777-1780
- Oksanen A, Sipponen P, Karttunen R, Miettinen A, Veijola L, Sarna S, Rautelin H. Atrophic gastritis and Helicobacter pylori infection in outpatients referred for gastroscopy. *Gut* 2000; **46**: 460-463
- Karnes WE Jr, Samloff IM, Siurala M, Kekki M, Sipponen P, Kim SW, Walsh JH. Positive serum antibody and negative tissue staining for Helicobacter pylori in subjects with atrophic body gastritis. *Gastroenterology* 1991; **101**: 167-174
- Annibale B, Negrini R, Caruana P, Lahner E, Grossi C, Bordi C, Delle Fave G. Two-thirds of atrophic body gastritis patients have evidence of Helicobacter pylori infection. *Helicobacter* 2001; **6**: 225-233
- Kokkola A, Kosunen TU, Puolakkainen P, Sipponen P, Harkonen M, Laxen F, Virtamo J, Haapiainen R, Rautelin H. Spontaneous disappearance of Helicobacter pylori antibodies in patients with advanced atrophic corpus gastritis. *APMIS* 2003; **111**: 619-624
- Ekstrom AM, Held M, Hansson LE, Engstrand L, Nyren O. Helicobacter pylori in gastric cancer established by CagA



- immunoblot as a marker of past infection. *Gastroenterology* 2001; **121**: 784-791
- 29 **Kuipers EJ**, Sipponen P. Helicobacter pylori eradication for the prevention of gastric cancer. *Helicobacter* 2006; **11** Suppl 1: 52-57
- 30 **Varis K**, Sipponen P, Laxen F, Samloff IM, Huttunen JK, Taylor PR, Heinonen OP, Albanes D, Sande N, Virtamo J, Harkonen M. Implications of serum pepsinogen I in early endoscopic diagnosis of gastric cancer and dysplasia. Helsinki Gastritis Study Group. *Scand J Gastroenterol* 2000; **35**: 950-956
- 31 **Bodger K**, Wyatt JL, Heatley RV. Variation in serum pepsinogens with severity and topography of Helicobacter pylori-associated chronic gastritis in dyspeptic patients referred for endoscopy. *Helicobacter* 2001; **6**: 216-224
- 32 **Sipponen P**, Ranta P, Helske T, Kaariainen I, Maki T, Linnala A, Suovaniemi O, Alanko A, Harkonen M. Serum levels of amidated gastrin-17 and pepsinogen I in atrophic gastritis: an observational case-control study. *Scand J Gastroenterol* 2002; **37**: 785-791
- 33 Sierra R, Mena F, Ramirez V, Mendez E, Salazar M, Une C, Kajiwara T. Pepsinógenos séricos para detectar cáncer gástrico en Costa Rica. *Acta Bioquím Clin Latinoam* 2003; **37**: 357-362
- 34 **Alpizar-Alpizar W**, Perez-Perez GI, Une C, Cuenca P, Sierra R. Association of interleukin-1B and interleukin-1RN polymorphisms with gastric cancer in a high-risk population of Costa Rica. *Clin Exp Med* 2005; **5**: 169-176
- 35 **Perez-Perez GI**, Garza-Gonzalez E, Portal C, Olivares AZ. Role of cytokine polymorphisms in the risk of distal gastric cancer development. *Cancer Epidemiol Biomarkers Prev* 2005; **14**: 1869-1873
- 36 **Furuta T**, El-Omar EM, Xiao F, Shirai N, Takashima M, Sugimura H. Interleukin 1beta polymorphisms increase risk of hypochlorhydria and atrophic gastritis and reduce risk of duodenal ulcer recurrence in Japan. *Gastroenterology* 2002; **123**: 92-105
- 37 **Figueiredo C**, Machado JC, Pharoah P, Seruca R, Sousa S, Carvalho R, Capelinha AF, Quint W, Caldas C, van Doorn LJ, Carneiro F, Sobrinho-Simoes M. Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma. *J Natl Cancer Inst* 2002; **94**: 1680-1687
- 38 **Camargo MC**, Mera R, Correa P, Peek RM Jr, Fontham ET, Goodman KJ, Piazuelo MB, Sicinschi L, Zabaleta J, Schneider BG. Interleukin-1beta and interleukin-1 receptor antagonist gene polymorphisms and gastric cancer: a meta-analysis. *Cancer Epidemiol Biomarkers Prev* 2006; **15**: 1674-1687
- 39 **Kato S**, Onda M, Yamada S, Matsuda N, Tokunaga A, Matsukura N. Association of the interleukin-1 beta genetic polymorphism and gastric cancer risk in Japanese. *J Gastroenterol* 2001; **36**: 696-699
- 40 **Lee SG**, Kim B, Choi W, Lee I, Choi J, Song K. Lack of association between pro-inflammatory genotypes of the interleukin-1 (IL-1B -31 C/+ and IL-1RN \*2/\*2) and gastric cancer/duodenal ulcer in Korean population. *Cytokine* 2003; **21**: 167-171
- 41 **Gatti LL**, Burbano RR, de Assumpcao PP, Smith Mde A, Payao SL. Interleukin-1beta polymorphisms, Helicobacter pylori infection in individuals from Northern Brazil with gastric adenocarcinoma. *Clin Exp Med* 2004; **4**: 93-98
- 42 **Kamangar F**, Abnet CC, Hutchinson AA, Newschaffer CJ, Helzlsouer K, Shugart YY, Pietinen P, Dawsey SM, Albanes D, Virtamo J, Taylor PR. Polymorphisms in inflammation-related genes and risk of gastric cancer (Finland). *Cancer Causes Control* 2006; **17**: 117-125
- 43 **Hatakeyama M**. Oncogenic mechanisms of the Helicobacter pylori CagA protein. *Nat Rev Cancer* 2004; **4**: 688-694
- 44 **Rebbeck TR**, Sankar P. Ethnicity, ancestry, and race in molecular epidemiologic research. *Cancer Epidemiol Biomarkers Prev* 2005; **14**: 2467-2471
- 45 **Zabaleta J**, Schneider BG, Ryckman K, Hooper PF, Camargo MC, Piazuelo MB, Sierra RA, Fontham ET, Correa P, Williams SM, Ochoa AC. Ethnic differences in cytokine gene polymorphisms: potential implications for cancer development. *Cancer Immunol Immunother* 2008; **57**: 107-114
- 46 **Kobayashi M**, Tsubono Y, Sasazuki S, Sasaki S, Tsugane S. Vegetables, fruit and risk of gastric cancer in Japan: a 10-year follow-up of the JPHC Study Cohort I. *Int J Cancer* 2002; **102**: 39-44
- 47 **Nomura AM**, Perez-Perez GI, Lee J, Stemmermann G, Blaser MJ. Relation between Helicobacter pylori cagA status and risk of peptic ulcer disease. *Am J Epidemiol* 2002; **155**: 1054-1059
- 48 **Atherton JC**. The clinical relevance of strain types of Helicobacter pylori. *Gut* 1997; **40**: 701-703
- 49 **Hansson LE**, Nyren O, Hsing AW, Bergstrom R, Josefsson S, Chow WH, Fraumeni JF Jr, Adami HO. The risk of stomach cancer in patients with gastric or duodenal ulcer disease. *N Engl J Med* 1996; **335**: 242-249
- 50 **Wu MS**, Chen CJ, Lin JT. Host-environment interactions: their impact on progression from gastric inflammation to carcinogenesis and on development of new approaches to prevent and treat gastric cancer. *Cancer Epidemiol Biomarkers Prev* 2005; **14**: 1878-1882

S- Editor Li DL E- Editor Ma WH

